Literature DB >> 22234950

Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies.

Pamela B DeGuzman1, Kwame O Akosah, Allan G Simpson, Kirk E Barbieri, Gregory C Megginson, Randal I Goldberg, George A Beller.   

Abstract

Guidelines recommend aggressive goals for lipid and blood pressure reduction for high risk patients with diabetes mellitus and atherosclerotic coronary disease. However, it remains unclear how many patients achieve treatment goals versus the number of people merely placed on treatment. We conducted an observational study in an academic cardiology clinic. A total of 926 patients with atherosclerotic cardiovascular disease and concomitant diabetes mellitus met criteria. Mean age was 68.4 ± 10.2, 65.6% were male, and 86.8% were Caucasian. By the last visit a high percentage of patients were receiving recommended medications. Mean LDL-cholesterol achieved was 80.4 mg/dl with 40.9% reaching ≤ 70 mg/dl, and 61.7% reaching SBP ≤ 130 mmHg. Many patients with diabetes mellitus and atherosclerotic cardiovascular disease are prescribed recommended medications; however, few achieve guidelines-specified therapeutic goals for LDL-cholesterol and blood pressure. Studies evaluating performance improvement should include percentage of patients reaching treatment goals. Mechanisms underlying the treatment gap need to be identified and addressed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234950     DOI: 10.1177/1479164111431471

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  5 in total

1.  Contributors to primary care guidelines: What are their professions and how many of them have conflicts of interest?

Authors:  G Michael Allan; Roni Kraut; Aven Crawshay; Christina Korownyk; Ben Vandermeer; Michael R Kolber
Journal:  Can Fam Physician       Date:  2015-01       Impact factor: 3.275

2.  Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia.

Authors:  Ylber Jani; Amet Kamberi; Fatmir Ferati; Atila Rexhepi; Bekim Pocesta; Nikola Orovcanec; Dali Lala; Gafur Polisi; Mair Iseni; Arben Mirto; Agim Zeqiri
Journal:  Am J Cardiovasc Dis       Date:  2014-06-28

Review 3.  A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.

Authors:  Hua Ling; John T Luoma; Daniel Hilleman
Journal:  Cardiol Res       Date:  2013-05-09

4.  Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.

Authors:  Ina-Maria Rückert; Michaela Schunk; Rolf Holle; Sabine Schipf; Henry Völzke; Alexander Kluttig; Karin-Halina Greiser; Klaus Berger; Grit Müller; Ute Ellert; Hannelore Neuhauser; Wolfgang Rathmann; Teresa Tamayo; Susanne Moebus; Silke Andrich; Christa Meisinger
Journal:  Cardiovasc Diabetol       Date:  2012-05-08       Impact factor: 9.951

5.  Effectiveness of general practice based, practice nurse led telephone coaching on glycaemic control of type 2 diabetes: the Patient Engagement and Coaching for Health (PEACH) pragmatic cluster randomised controlled trial.

Authors:  Irene D Blackberry; John S Furler; James D Best; Patty Chondros; Margarite Vale; Christine Walker; Trisha Dunning; Leonie Segal; James Dunbar; Ralph Audehm; Danny Liew; Doris Young
Journal:  BMJ       Date:  2013-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.